# Manufacturing cost and time for living and radioactive medicines

Source: https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/  
OnCo record `b-manufacturing-cell-therapy` (Bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.

## Summary

Autologous CAR-T, TIL and TCR-T are one-batch-per-patient manufacturing: leukapheresis, shipping, transduction, expansion, release testing and return take several weeks, during which some patients progress or die, a proportion of products fail specification, and list prices run to several hundred thousand dollars before hospital costs. Only a small fraction of eligible patients receive approved CAR-T because of slot availability, referral and cost. Radioligand therapy has a different supply problem: lutetium-177 depends on a handful of reactors and enrichment sources, and actinium-225 for alpha therapy has been limited to a few curies a year worldwide from thorium-229 stocks, with accelerator and thorium-based production only now scaling. ADCs and bispecifics have complex biologics supply chains with a small number of contract manufacturers. In vivo CAR generation, allogeneic products, point-of-care and automated manufacturing, and new isotope production routes are the technical answers.

## Fields

- Kind: Bottleneck
- Last checked: 2026-09-08
- Stage: regulation-manufacturing
- Severity: major
- Metrics: Estimated total cost of CAR-T therapy including list price and management of adverse events (2018 US analysis): Up to ~US$500,000 per patient (Hernandez, Prasad & Gellad, JAMA Oncology 2018); Patients in ELIANA for whom tisagenlecleucel could not be manufactured: 7 of 92 enrolled (Maude et al., NEJM 2018); Historic global actinium-225 supply from thorium-229 stockpiles: ~63 GBq (1.7 Ci) per year (Robertson et al., Current Radiopharmaceuticals 2018)
- Causes: Autologous products are bespoke batches with no economies of scale.; Viral vector and GMP capacity are limited and expensive.; Actinium-225 has historically come only from decay of legacy thorium-229 held by a few government laboratories.; Lutetium-177 production depends on reactor time and enriched target material from few suppliers.; Release testing, cold-chain logistics and hospital accreditation add weeks and cost that no design optimisation removes.

## Sources

- Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977
- Maude et al., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA, NEJM 2018): https://doi.org/10.1056/NEJMoa1709866
- US Department of Energy Isotope Program: https://www.isotopes.gov/

## Connected records

- roadmaps: [Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR](https://onco.cc/roadmaps/cell-therapy-roadmap/), [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/), [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://onco.cc/roadmaps/radiopharma-roadmap/)
- ideas: [A coordinated reserve and shared schedule for the world's medical isotope reactors](https://onco.cc/ideas/idea-reg-medical-isotope-reactor-reserve/), [A global medical isotope supply observatory with forecasts and shortage alerts](https://onco.cc/ideas/idea-reg-isotope-supply-observatory/), [A neutral slot exchange so unused CAR-T manufacturing slots go to the next patient](https://onco.cc/ideas/idea-reg-manufacturing-slot-exchange/), [A university cyclotron network with shared regulatory files for new tracers](https://onco.cc/ideas/idea-fund-academic-radiopharma-pipeline/), [An open interoperability standard for closed automated cell-processing machines](https://onco.cc/ideas/idea-reg-closed-manufacturing-interop-standard/), [Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier](https://onco.cc/ideas/idea-reg-yb176-enrichment-capacity/), [Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy](https://onco.cc/ideas/idea-reg-early-apheresis-banking/), [Comparability by design: a digital twin and sentinel panel for cell process changes](https://onco.cc/ideas/idea-reg-comparability-by-design-digital-twin/), [Continuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze](https://onco.cc/ideas/idea-reg-hpapi-continuous-flow/), [Digital batch records and AI process control to halve cell therapy batch failures](https://onco.cc/ideas/idea-reg-ai-process-control-cell-manufacturing/), [Full refund for CAR-T if the patient has not responded at three months](https://onco.cc/ideas/idea-reg-cart-outcomes-refund/), [Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211](https://onco.cc/ideas/idea-reg-alpha-emitter-portfolio/), [Harmonise Europe's hospital exemption for academic cell therapies, with one registry](https://onco.cc/ideas/idea-reg-hospital-exemption-harmonised/), [Head-to-head bispecific vs CAR-T in second-line LBCL](https://onco.cc/ideas/idea-bispecific-vs-car-t-second-line/), [Hospital-based CAR-T manufacturing at cost through a public network](https://onco.cc/ideas/idea-fund-public-car-t-manufacturing/), [Hospital-exemption cell therapies at scale, backed by a shared registry](https://onco.cc/ideas/idea-fund-hospital-exemption-registry/), [Hospital-made CAR-T under one shared regulatory master file](https://onco.cc/ideas/idea-reg-point-of-care-cart-network/), [In vivo CAR-T against solid-tumour antigens](https://onco.cc/ideas/idea-in-vivo-car-solid/), [In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma](https://onco.cc/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/), [In vivo CAR-T manufactured and priced like a generic biologic](https://onco.cc/ideas/idea-moon-in-vivo-cart-generic-price/), [Mandatory public reporting of vein-to-vein time and failure rate per CAR-T product](https://onco.cc/ideas/idea-reg-vein-to-vein-public-benchmark/), [Manufacturing-change passport: one approved CMC change accepted everywhere in 30 days](https://onco.cc/ideas/idea-reg-manufacturing-change-passport/), [Mutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants](https://onco.cc/ideas/idea-reg-mutual-recognition-inspections-atmp/), [Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T](https://onco.cc/ideas/idea-reg-open-source-lentiviral-vectors/), [Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route](https://onco.cc/ideas/idea-reg-non-viral-cart-manufacturing/), [Off-the-shelf natural killer cells to sweep up residual disease](https://onco.cc/ideas/idea-bio2-nk-cells-for-mrd/), [Open the barrier so engineered immune cells can enter the brain](https://onco.cc/ideas/idea-bio2-fus-for-cell-entry/), [Pay for one-time curative therapies as an annuity that stops at relapse](https://onco.cc/ideas/idea-reg-annuity-payment-durable-therapies/), [Personalised vaccines given only when the blood test turns positive](https://onco.cc/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/), [Plan the second CAR-T target before the first one is lost](https://onco.cc/ideas/idea-bio1-adaptive-car-antigen-switch/), [Platform designation for ADC linker-payloads so manufacturing data carry across](https://onco.cc/ideas/idea-reg-adc-platform-designation/), [Public cell-therapy foundries at cancer centres for academics and start-ups](https://onco.cc/ideas/idea-reg-public-cell-therapy-foundries/), [Public payers cover academic CAR-T at cost as a benchmark for commercial prices](https://onco.cc/ideas/idea-reg-academic-cart-at-cost-coverage/), [Public reference standards and potency assays for CAR-T so every lab measures alike](https://onco.cc/ideas/idea-reg-cart-potency-reference-standards/), [Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000](https://onco.cc/ideas/idea-reg-lmic-public-cart-manufacturing/), [Qualify one iPSC master cell bank once for many off-the-shelf cell products](https://onco.cc/ideas/idea-reg-ipsc-master-bank-qualified-once/), [Recover legacy radium-226 sources worldwide as the feedstock for actinium-225](https://onco.cc/ideas/idea-reg-legacy-radium-recovery-ac225/), [Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit](https://onco.cc/ideas/idea-reg-ac225-accelerator-pharmacopoeia/), [Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes](https://onco.cc/ideas/idea-reg-regional-radiopharmacy-hubs/), [Regional translational institutes with academic GMP suites and IND teams](https://onco.cc/ideas/idea-fund-translational-institutes-gmp/), [Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote](https://onco.cc/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/), [Select patients for cell therapy by whether their tumour holds reactive T cells](https://onco.cc/ideas/idea-bio2-til-reactivity-selection/), [Shared modular GMP facilities for academic personalised vaccines and cell products](https://onco.cc/ideas/idea-fund-shared-personalised-therapy-gmp/), [Two-day CAR-T manufacture paired with rapid release tests that regulators accept](https://onco.cc/ideas/idea-reg-two-day-cart-rapid-release/), [Use patient organoids to check a cell therapy will work before infusing it](https://onco.cc/ideas/idea-bio1-organoid-cell-therapy-potency/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Melanoma](https://onco.cc/cancers/melanoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Post-transplant lymphoproliferative disorder (PTLD)](https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://onco.cc/technologies/actinium-225-supply/), [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [Allogeneic cell banks: one donor, hundreds of doses](https://onco.cc/technologies/allogeneic-cell-banks/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/), [Research reactors for medical isotopes (Mo-99, Lu-177, I-131)](https://onco.cc/technologies/research-reactor-isotope-production/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/), [The ADC supply chain (antibody, payload-linker, conjugation, fill)](https://onco.cc/technologies/adc-supply-chain/), [TIL therapy](https://onco.cc/technologies/til-therapy/)
- drugs: [Actinium-225 PSMA agents](https://onco.cc/drugs/ac225-psma/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [Lifileucel](https://onco.cc/drugs/lifileucel/), [Lutetium-177 dotatate](https://onco.cc/drugs/lutathera/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/), [Talicabtagene autoleucel](https://onco.cc/drugs/talicabtagene-autoleucel/), [Tisagenlecleucel](https://onco.cc/drugs/tisagenlecleucel/), [Varnimcabtagene autoleucel](https://onco.cc/drugs/varnimcabtagene-autoleucel/)
- companies: [Allogene Therapeutics](https://onco.cc/companies/allogene/), [Caribou Biosciences](https://onco.cc/companies/caribou/), [Cellogen Therapeutics](https://onco.cc/companies/cellogen/), [Curium](https://onco.cc/companies/curium/), [Fate Therapeutics](https://onco.cc/companies/fate-therapeutics/), [Immuneel Therapeutics](https://onco.cc/companies/immuneel/), [ImmunoACT](https://onco.cc/companies/immunoact/), [Interius BioTherapeutics](https://onco.cc/companies/interius/), [Iovance Biotherapeutics](https://onco.cc/companies/iovance/), [ITM Isotope Technologies Munich](https://onco.cc/companies/itm/), [JW Therapeutics](https://onco.cc/companies/jw-therapeutics/), [Novartis](https://onco.cc/companies/novartis/), [Orano Med](https://onco.cc/companies/orano-med/), [Orna Therapeutics (Eli Lilly)](https://onco.cc/companies/orna-therapeutics/), [Sana Biotechnology](https://onco.cc/companies/sana-biotechnology/), [TerraPower Isotopes](https://onco.cc/companies/terrapower-isotopes/), [Umoja Biopharma](https://onco.cc/companies/umoja-biopharma/), [WuXi AppTec](https://onco.cc/companies/wuxi-apptec/)
- terms: [Alpha vs beta emitters](https://onco.cc/terms/alpha-vs-beta/), [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [Dosimetry](https://onco.cc/terms/dosimetry/), [ICANS (neurotoxicity)](https://onco.cc/terms/icans/), [Theranostics](https://onco.cc/terms/theranostics/)
- trials: [CARTITUDE-4](https://onco.cc/trials/cartitude-4/), [ELARA](https://onco.cc/trials/elara/), [ELIANA](https://onco.cc/trials/eliana/), [IMAGINE (varnimcabtagene autoleucel, Immuneel)](https://onco.cc/trials/imagine-varnimcabtagene/), [JULIET](https://onco.cc/trials/juliet/), [Talicabtagene autoleucel (NexCAR19) phase 1/2](https://onco.cc/trials/talicel-phase-1-2/), [TRANSCEND NHL 001](https://onco.cc/trials/transcend-nhl-001/), [VISION](https://onco.cc/trials/vision/), [ZUMA-7](https://onco.cc/trials/zuma-7/)
- key papers: [Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies](https://onco.cc/key-papers/paper-besser-til-melanoma-intent-to-treat-ccr-2013/), [Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial](https://onco.cc/key-papers/paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022/), [C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed](https://onco.cc/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/), [CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/), [CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy](https://onco.cc/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/), [DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer](https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/), [ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL](https://onco.cc/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/), [EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T](https://onco.cc/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/), [Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity](https://onco.cc/key-papers/paper-gross-eshhar-chimeric-receptor-pnas-1989/), [JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/), [KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma](https://onco.cc/key-papers/paper-karmma-3-ide-cel-nejm-2023/), [KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery](https://onco.cc/key-papers/paper-keynote-942-lancet-2024/), [Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study](https://onco.cc/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/), [Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL](https://onco.cc/key-papers/paper-maude-ctl019-all-nejm-2014/), [Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma](https://onco.cc/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/), [Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer](https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/), [Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma](https://onco.cc/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/), [Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma](https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/), [SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma](https://onco.cc/key-papers/paper-spearhead-1-lancet-2024/), [Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study](https://onco.cc/key-papers/paper-jain-talicabtagene-lancet-haem-2025/), [Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial](https://onco.cc/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/), [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/), [TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma](https://onco.cc/key-papers/paper-transform-liso-cel-lancet-2022/), [UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL](https://onco.cc/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/), [ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma](https://onco.cc/key-papers/paper-zuma-1-axi-cel-nejm-2017/), [ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early](https://onco.cc/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/)
- people: [Jacob Schachter](https://onco.cc/people/jacob-schachter/), [Michal Besser](https://onco.cc/people/michal-besser/), [Polina Stepensky](https://onco.cc/people/polina-stepensky/), [Rahul Purwar](https://onco.cc/people/purwar-rahul/), [Sanford I. Weill](https://onco.cc/people/sanford-weill/), [Zelig Eshhar](https://onco.cc/people/zelig-eshhar/)
- institutions: [Children's Hospital of Philadelphia](https://onco.cc/institutions/chop/), [Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine](https://onco.cc/institutions/baylor-duncan/), [Department of Biotechnology, Government of India](https://onco.cc/institutions/dbt-india/), [Frederick National Laboratory for Cancer Research](https://onco.cc/institutions/frederick-national-lab/), [Great Ormond Street Hospital for Children](https://onco.cc/institutions/great-ormond-street/), [Hadassah Medical Center](https://onco.cc/institutions/hadassah/), [Hospital Clínic de Barcelona / IDIBAPS](https://onco.cc/institutions/hospital-clinic-barcelona/), [Indian Institute of Technology Bombay](https://onco.cc/institutions/iit-bombay/), [Paul-Ehrlich-Institut](https://onco.cc/institutions/paul-ehrlich-institut/), [Sheba Medical Center](https://onco.cc/institutions/sheba/), [The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute](https://onco.cc/institutions/ottawa-hospital/)

---
JSON: https://onco.cc/api/v1/entities/b-manufacturing-cell-therapy.json